



**EFFECTS ON INFANT GROWTH AND  
NEURODEVELOPMENT OF REPEAT DOSE  
PRENATAL CORTICOSTEROIDS TO  
WOMEN AT RISK OF PRETERM BIRTH:  
A RANDOMISED CONTROLLED TRIAL.**

---

**KRISTIN JANE M<sup>C</sup>LAUGHLIN**

---

Thesis submitted in fulfillment of the requirements for  
the degree of Doctor of Philosophy

January 2003

DEPARTMENT OF OBSTETRICS & GYNAECOLOGY  
FACULTY OF HEALTH SCIENCES  
THE UNIVERSITY OF ADELAIDE

# TABLE OF CONTENTS

<b>Table of Contents</b> .....	<b>i</b>
<b>List of Tables</b> .....	<b>iii</b>
<b>List of Figures</b> .....	<b>vii</b>
<b>Abstract</b> .....	<b>x</b>
<b>Declaration</b> .....	<b>xii</b>
<b>Acknowledgements</b> .....	<b>xiii</b>
<b>Author's Contribution</b> .....	<b>xv</b>
<b>1. Literature Review</b> .....	<b>1</b>
1.1 Purpose and scope.....	1
1.2 Preterm birth.....	1
1.3 Single course prenatal corticosteroids.....	4
1.4 Repeat prenatal corticosteroids.....	18
1.5 The ACTORDS Trial.....	51
1.6 The aims and hypotheses of the studies in this thesis.....	53
<b>2. Methods</b> .....	<b>56</b>
2.1 Eligibility and trial entry.....	57
2.2 Anthropometric assessments.....	58
2.3 Neurodevelopmental assessments.....	62
2.4 Primary study endpoints.....	67
2.5 Sample size.....	67
2.6 Data collection and management.....	67
2.7 Data analysis.....	69

<b>3. Results of Repeat Prenatal Corticosteroids and Infant Growth.....</b>	<b>78</b>
3.1 Introduction.....	78
3.2 Aims and hypotheses.....	78
3.3 Summary of methods.....	79
3.4 Results.....	80
3.5 Discussion.....	154
<b>4. Results of Repeat Prenatal Corticosteroids and Early</b>	
<b>Infant Neurodevelopment.....</b>	<b>173</b>
4.1 Introduction.....	173
4.2 Aims and hypotheses.....	173
4.3 Summary of methods.....	174
4.4 Results.....	175
4.5 Discussion.....	195
<b>5. Overall Conclusions.....</b>	<b>203</b>
<b>6. Appendices.....</b>	<b>206</b>
6.1 Patient information sheet and consent form.....	206
6.2 Growth data forms.....	210
6.3 Four and eight month Ages and Stages Questionnaires.....	212
<b>7. References .....</b>	<b>222</b>

## LIST OF TABLES

1.4.2.1	Designation of levels of evidence.....	20
1.4.4.1	Methodology of randomised controlled trials of repeat prenatal corticosteroids.....	29
1.4.4.2	Methods of systematic review and meta-analysis of observational studies reporting size at birth.....	38
2.3.1.1	Validation of ASQ.....	63
3.4.1.1	Maternal demographics, obstetric history and reason for risk of preterm birth at trial entry.....	82
3.4.1.2	Gestation at ACTORDS trial entry and number of ACTORDS treatment doses received.....	84
3.4.1.3	Birth and infant clinical outcomes.....	85
3.4.2.1	Weight by treatment group.....	87
3.4.2.2.	Estimated mean weight at the nominal measurement time points.....	88
3.4.2.3	Weight z-scores by treatment group.....	95
3.4.2.4	Estimated mean weight z-scores by the nominal measurement time points.....	96
3.4.2.5	Weight percentiles by treatment group.....	103
3.4.3.1	Total body length by treatment group.....	105
3.4.3.2	Estimated mean total body length at the nominal measurement time points.....	106
3.4.3.3	Total body length z-scores by treatment group.....	113

3.4.3.4	Estimated total body length z-scores by the nominal measurement time points.....	114
3.4.3.5	Total body length percentiles by treatment group.....	121
3.4.4.1	Head circumference by treatment group.....	123
3.4.4.2	Estimated mean head circumference at the nominal measurement time points.....	124
3.4.4.3	Head circumference z-scores by treatment group.....	131
3.4.4.4	Estimated mean head circumference z-score for nominal measurement time points.....	132
3.4.4.5	Head circumference percentiles by treatment group.....	139
3.4.5.1	Knee-ankle length by treatment group.....	141
3.4.5.2	Estimated mean knee-ankle length at the nominal measurement time points.....	142
3.4.6.1	Ponderal index by treatment group.....	149
3.4.7.1	Gestational age at birth and the number of ACTORDS treatment doses received.....	151
3.4.7.2	Gestational age at birth and the latency between the last ACTORDS treatment dose and birth.....	151
3.4.7.3	The number of ACTORDS treatment doses received and the latency from the last ACTORDS treatment dose to birth.....	152
3.4.8.1	Summary of the main effects of repeat prenatal corticosteroids on size at birth and early infant growth.....	153

4.4.2.1	Maternal demographics, obstetric history and reason for risk of preterm birth at trial entry by ASQ receipt.....	178
4.4.2.2	Gestation at ACTORDS trial entry and number of ACTORDS treatment doses received by ASQ receipt.....	179
4.4.2.3	Birth and infant clinical outcomes by ASQ receipt.....	179
4.4.2.4	Maternal demographics, obstetric history and reason for risk of preterm birth at trial entry for women with infants for whom ASQ were received.....	181
4.4.2.5	Gestation at ACTORDS trial entry and number of ACTORDS treatment doses received for women with infants for whom ASQ were received.....	182
4.4.2.6	Birth and infant clinical outcomes for women and their infants for whom ASQ were received.....	183
4.4.2.7	Four month median ASQ scores.....	184
4.4.2.8	Eight month median ASQ scores.....	184
4.4.2.9	Four month ASQ general questions.....	185
4.4.2.10	Eight month ASQ general questions.....	185
4.4.2.11	Estimated means for mixed model analysis of variance of ASQ scores..	186
4.4.2.12	Four and eight month ASQ developmental domain cut-off scores and adjusted relative risks.....	187
4.4.3.1	Maternal demographics, obstetric history and reason for risk of preterm birth at trial entry by FTII completion.....	189
4.4.3.2	Gestation at ACTORDS trial entry and number of ACTORDS treatment doses received by FTII completion.....	190

4.4.3.3	Birth and infant clinical outcomes by FTII completion.....	190
4.4.3.4	Maternal demographics, obstetric history and reason for risk of preterm birth at trial entry for women whose infants were tested using the FTII...	192
4.4.3.5	Gestation at ACTORDS trial entry and number of ACTORDS treatment doses received for women whose infants were tested with the FTII.....	193
4.4.3.6	Birth and infant clinical outcomes for women and their infants who were tested using the FTII.....	193
4.4.3.7	Fagan Test of Infant Intelligence.....	194

## LIST OF FIGURES

1.3.4.1	Birth weight (grams) after single course prenatal corticosteroids compared with placebo/control/no treatment.....	10
1.4.4.1	Meta-analysis of observational studies: birth weight (grams).....	40
1.4.4.2	Meta-analysis of observational studies: birth weight less than the 10 <sup>th</sup> percentile for gestation at birth.....	40
2.0.1.1	Infant growth measurement time points.....	56
2.2.1.1	Measuring knee-ankle length with the neonatal knemometer.....	61
2.3.1.1	Developmental domains of the Ages and Stages Questionnaires.....	62
2.3.2.1	The Fagan Test of Infant Intelligence.....	66
3.4.1.1	In-depth Growth and Neurodevelopment Trial Profile.....	80
3.4.2.1	Weight growth curves by corrected age.....	86
3.4.2.2	Estimated mean weight and 95% CI.....	89
3.4.2.3	Estimated mean weight and 95% CI by gestational age at birth.....	91
3.4.2.4	Estimated mean weight and 95% CI by the number of ACTORDS treatment doses received.....	92
3.4.2.5	Estimated mean weight and 95% CI by the latency from last ACTORDS dose to birth.....	93
3.4.2.6	Estimated mean weight z-score and 95% CI.....	97
3.4.2.7	Estimated mean weight z-score and 95% CI by gestational age at birth...	99
3.4.2.8	Estimated mean weight z-score and 95% CI by the number of ACTORDS treatment doses received.....	100



3.4.2.9	Estimated mean weight z-score and 95% CI by the latency from last ACTORDS dose to birth.....	101
3.4.3.1	Total body length growth curves by corrected age.....	104
3.4.3.2	Estimated mean total body length and 95% CI.....	107
3.4.3.3	Estimated mean total body length and 95% CI by gestational age at birth.....	109
3.4.3.4	Estimated mean total body length and 95% CI by the number of ACTORDS treatment doses received.....	110
3.4.3.5	Estimated mean total body length and 95% CI by the latency from last ACTORDS dose to birth.....	111
3.4.3.6	Estimated mean total body length z-score and 95% CI .....	115
3.4.3.7	Estimated mean total body length z-score and 95% CI by gestational age at birth.....	117
3.4.3.8	Estimated mean total body length z-score and 95% CI by the number of ACTORDS treatment doses received.....	118
3.4.3.9	Estimated mean total body length z-score and 95% CI by the latency from the last ACTORDS dose to birth.....	119
3.4.4.1	Head circumference growth curves by corrected age.....	122
3.4.4.2	Estimated mean head circumference and 95% CI.....	125
3.4.4.3	Estimated mean head circumference and 95% CI by gestational age at birth.....	127
3.4.4.4	Estimated mean head circumference and 95% CI by the number of ACTORDS treatment doses received.....	128

3.4.4.5	Estimated mean head circumference and 95% CI by the latency from last ACTORDS dose to birth.....	129
3.4.4.6	Estimated mean head circumference z-score and 95% CI.....	133
3.4.4.7	Estimated mean head circumference z-score and 95% CI by gestational age at birth.....	135
3.4.4.8	Estimated mean head circumference z-score and 95% CI by the number of ACTORDS doses received .....	136
3.4.4.9	Estimated mean head circumference z-score and 95% CI by the latency from last ACTORDS dose to birth.....	137
3.4.5.1	Knee-ankle length growth curves by corrected age.....	140
3.4.5.2	Estimated mean knee-ankle length and 95% CI.....	143
3.4.5.3	Estimated mean knee-ankle length and 95% CI by gestational age at birth.....	145
3.4.5.4	Estimated mean knee-ankle length and 95% CI by the number of ACTORDS treatment doses received.....	146
3.4.5.5.	Estimated mean knee-ankle length and 95% CI by the latency from last ACTORDS dose to birth.....	147
3.4.6.1	Estimated mean ponderal index ( $\text{g}/\text{cm}^3$ ) and 95% CI.....	150
4.4.1.1	In-depth Growth and Neurodevelopment Trial Profile .....	175

# ABSTRACT

## Introduction

A single course of prenatal corticosteroids offers no benefits for infants born seven days after treatment. Repeat corticosteroid treatment may improve health outcomes, but with possible adverse effects. This thesis aimed to examine the effects of repeat prenatal corticosteroids on infant growth and neurodevelopment.

## Methods

Women at risk of preterm birth more than seven days after a single course of prenatal corticosteroids, who gave informed written consent, were randomised to receive weekly repeat dose corticosteroids or placebo, if still at risk, until 32 weeks gestation. Infant growth was assessed at birth, day three, weekly to four weeks, monthly to four months of age and at 7¼ months corrected age (CA). Neurodevelopmental milestones were assessed at four and eight months CA and novelty preference at 7¼ months CA.

## Results

One hundred and forty seven infants were randomised. Repeat corticosteroid treatment reduced the weight z-score at birth, four months following birth and at 7¼ months CA, compared with placebo. Total body length z-score and knee-ankle length were reduced at birth for repeat corticosteroid infants, compared with placebo. Total body length z-score was unaffected by repeat corticosteroid treatment from day three to 7¼ months CA. Knee-ankle length was reduced with repeat corticosteroid exposure up to three months following birth, compared with placebo. Head circumference z-scores were unaffected by repeat

corticosteroid treatment from birth to 7¼ months CA. Repeat corticosteroids reduced personal-social development at eight, but not four months CA, compared with placebo. Repeat corticosteroids did not reduce communication, gross motor, fine motor and problem solving scores at four or eight months CA, did not increase the number of infants screened at risk of developmental delay and did not reduce novelty preference, compared with placebo.

### **Conclusions**

Repeat prenatal corticosteroids reduce weight, length and knee-ankle length at birth, although only infant weight remained reduced at 7¼ months CA. No adverse effects on infant neurodevelopment were seen for repeat corticosteroid treated infants, apart from a reduction in personal-social development at eight months CA. Confirmation of and further assessment as to the long-term consequences of these observed effects is required.

## **DECLARATION**

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to a copy of my thesis, when deposited in the University Library, being available for loan and photocopy.

Kristin McLaughlin

January 2003

## ACKNOWLEDGEMENTS

It is a pleasure to thank the many people who have supported me in the production of this thesis. I would like to thank my supervisor, Associate Professor Caroline Crowther, for her guidance, support and inspiration throughout the course of this work. I am most grateful to all the women, their infants and families who have participated in this trial.

I would like to thank the ACTORDS Trial steering committee for allowing me to work as part of the ACTORDS team. Thank you to the staff of the Women's and Children's Hospital, Adelaide, for their assistance with this project. Thank you to Pat Ashwood, ACTORDS Trial Coordinator, for her help in recruiting women to this trial and in the collection of trial entry, birth and clinical neonatal data. I thank Professor Jeffrey Robinson and Associate Professor Ross Haslam for their helpful discussions on infant growth and neurodevelopment.

Special thanks to the staff of the Maternal and Perinatal Clinical Trials Unit, for their support, for their confidence in me, and for their continuous supply of cake! Thank you to Sarah Russell for her construction of the database used for data entry and data management and to Kristyn Willson for her patience and good humour in guiding me through the statistical analyses.

I would like to thank Meaghan Coyle, Dr Jodie Dodd, Alice Rumbold and Dr Caroline Smith for the support and encouragement only fellow PhD students can provide. I would like to thank Pam Carroll and Aaron McLaughlin for just being there. To my family, friends and partner for their support and patience in the completion of this project.

Financial support for these studies came from a variety of sources that included the National Health and Medical Research Council, the Channel 7 Research Foundation, the Women's and Children's Hospital Research Foundation and the Ramaciotti Foundation. Thank you to the Perinatal Society of Australia and New Zealand for financial support to attend the Perinatal Society conferences. Finally, I am indebted to the Department of Obstetrics and Gynaecology at The University of Adelaide, for their support throughout my candidature.

## **AUTHOR'S CONTRIBUTION**

I was responsible for the conceptualisation, design and development of the protocols and coordination of The In-depth Growth and Neurodevelopment Trial. I sought ethics approval from the Women's and Children's Hospital Ethics Committee for the trial, developed the data collection forms and obtained the required equipment (excepting the neonatal knemometer). I was responsible for arranging all appointments for the growth and neurodevelopmental assessments and pursuing missed appointments. All growth and neurodevelopmental data were collected by myself, at the Women's and Children's Hospital, at other local and regional hospitals or by home visit as required. I was responsible for sending all four and eight month neurodevelopment questionnaires and pursuing overdue developmental questionnaires by post and telephone and traced 'lost' participants in the trial by telephone when required.

The ACTORDS Trial (Australasian Collaborative Trial of Repeat Doses of Corticosteroids for the Prevention of Neonatal Respiratory Disease) coordinator, Ms Pat Ashwood, primarily conducted recruitment to the ACTORDS Trial and the completion of the ACTORDS Trial data forms, though I assisted in these tasks when required.

I was responsible for the entry and cleaning of all the data presented in this thesis. I undertook all statistical analyses, with guidance from Ms Kristyn Willson, our statistician.